Navigation Links
Study Finds Exergen Temporal Artery Thermometry Accurate on Newborns
Date:4/18/2011

WATERTOWN, Mass., April 18, 2011 /PRNewswire/ -- Measuring the body temperatures of newborns with temporal artery thermometry (forehead scanning) provides readings comparable to results obtained by axillary (under arm) thermometry, the clinically recommended method for this patient population, but causes less discomfort, according to a new study reported in Advances in Neonatal Care.  

The study(1), the first published clinical analysis evaluating the accuracy of temporal artery thermometry in neonates, compared the accuracy of temporal artery and axillary temperature readings as well as the discomfort level of newborns while obtaining the temperature readings. The sample included stable, mostly normothermic newborns with a gestational age between 32 and 40 weeks at birth hospitalized in a neonatal intensive care unit (NICU).  Rectal thermometry was used as the reference.

Researchers noted that axillary temperatures measured with an electronic thermometer probe are difficult to obtain without disturbing newborns, such disturbances causing increased respiratory and heart rates and lower oxygen saturation.  During the study, measurements taken using temporal artery thermometry resulted in a statistically significant improvement in comfort scores.  

An excerpt from the published study confirms this: "Neonates experienced less discomfort with the temporal artery thermometer than with the axillary thermometer method."  In addition, the authors stated: "The statistical equivalency of the temporal artery and axillary temperatures, coupled with less discomfort to the neonate during temporal artery device use, makes the temporal artery thermometer an attractive alternative for temperature monitoring in neonates."

"This independent research validates our findings about the usefulness of temporal artery thermometry," said Francesco Pompei, Ph.D., CEO of Exergen Corp. "Exergen's patented TemporalScanner™ Thermometer was developed in response to healthcare providers' and caregivers' at home need for a gentle, noninvasive, and accurate method of thermometry for all ages, from newborns to geriatrics."

The clinical research, which used an infra-red electronic temperature device made by Exergen Corp., was conducted at a level IIIa NICU in a not-for-profit hospital in the Western United States. It showed body temperature readings taken at the temporal artery and the clinically recommended under the arm method were similarly accurate when compared to rectal thermometry. The amount of deviation from the reference readings was within the standard set for noninvasive temperature measurement.

The study was not affiliated with Exergen and neither the authors nor the institution received compensation from the company to conduct the research.

Exergen markets two models of the TemporalScanner thermometer: a professional version for doctors' offices and hospitals, and a consumer model sold in major retailers including Wal-Mart, Target, Walgreen's, Costco, Sam's Club, Babies "R" Us, Toys "R" Us, and BJ's. More than 800 million temperatures are taken each year with the TemporalScanner. Used in thousands of hospitals, clinics, and pediatricians' offices in the country as well as in millions of homes, it is also the only thermometer manufactured in the United States.  

Exergen Corporation is recognized worldwide as an innovator and leading manufacturer of patented infrared thermometers, scanners, sensors and controls. The company holds more than 60 U.S. patents for non-invasive temperature measurement devices. Its products are used in a wide variety of industrial and medical applications for both professionals and consumers. For additional information, visit www.exergen.com.

(1) Gail Lee, RN, et al; Accuracy of Temporal Artery Thermometry in Neonatal Intensive Care Infants, in Advances in Neonatal Care,  Vol. 11, No. 1, pp 62-70.


'/>"/>
SOURCE Exergen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Letter to Health Care Providers Results in Reduction of Potentially Unsafe Concurrent Use of Plavix and Proton Pump Inhibitors
2. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
3. Adeonas Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper
4. Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting
5. Analytical Bio-Chemistry (ABC) Laboratories Implements eStudy™ Hosted Platform to Support its Ecotoxicology and Other Service Offerings
6. Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome
7. Max Neeman International Completes Targeted Enrollment of 15,000 for Large Ph IV Study
8. DURECT Announces ELADUR® (TRANSDUR®-Bupivacaine) Phase II Study Results in Chronic Low Back Pain
9. New Published Study Finds Masimo SET® Delivers More Reliable Measurements Significantly Faster Than Other Pulse Oximetry Technologies
10. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
11. Study Highlights Successes of Ascension Health Quality Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Dec. 6, 2016  BioAtla, LLC, a ... of Conditionally Active Biologic (CAB) antibody therapeutics, ... Group Company, Limited (Sinobioway) selected their first ... specific program candidates and the targeted indications ... and Sinobioway entered into a strategic collaboration ...
(Date:12/6/2016)... HASTINGS ON HUDSON, N.Y. , Dec. 6, ... anxiety, there,s now a reason to be hopeful. ... the way to a less anxious life. ... Robert Buck, the psychotherapist ... they represent a breakthrough approach to overcoming anxiety ...
(Date:12/5/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... previously-announced cash tender offers (the "Offers") for the ... the "Notes"), approximately $2.6 billion in aggregate principal amount ... withdrawn on or prior to 5:00 p.m., ... 5, 2016 (the "Early Tender Deadline"). The Company ...
Breaking Medicine Technology:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... the impact of new federal healthcare regulations at the 7th annual Health IT ... Atlanta. , Andy Slavitt, acting administrator for the Centers for Medicare & Medicaid ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, ... offering HIAC particle counting and sizing services for USP 788 and 789 particulate ... new service as a response to the needs of pharmaceutical and medical device ...
(Date:12/6/2016)... ... 2016 , ... 'Tis the season for family, festivity, food and fun! Temptation ... season when eating healthy, staying active, and taking medication and doing daily foot health ... , "Shopping trips, parties and family gatherings can take their toll on our ...
(Date:12/6/2016)... ... December 06, 2016 , ... The OSHA ... Training Institute Education Center headquartered in Northern California, has announced the addition of ... safety and health training to public sector employees. , “The primary goal of ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward Buckingham MD , ... arrival of the newest Sciton laser in January 2017. The Halo is the ... and ablative wavelengths for exceptional results. Outperforming more traditional lasers, the innovative Halo ...
Breaking Medicine News(10 mins):